PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: CUSTOMER LANDSCAPE PART 08: MARKET SEGMENTATION BY END-USER • Segmentation by end-user • Comparison by end-user • MHDs – Market size and forecast 2017-2022 • NDDs – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by end-user PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Increasing awareness programs • Increased adoption of new-generation drugs • Advances in technology in treating mental disorders PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Eli Lilly • F. Hoffmann-La Roche • Johnson & Johnson • Merck • Novartis PART 15: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global healthcare market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Customer landscape Exhibit 19: End-user – Market share 2017-2022 (%) Exhibit 20: Comparison by end-user Exhibit 21: MHDs – Market size and forecast 2017-2022 ($ mn) Exhibit 22: MHDs – Year-over-year growth 2018-2022 (%) Exhibit 23: NDDs – Market size and forecast 2017-2022 ($ mn) Exhibit 24: NDDs – Year-over-year growth 2018-2022 (%) Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Others – Year-over-year growth 2018-2022 (%) Exhibit 27: Market opportunity by end-user Exhibit 28: Global – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 35: APAC – Year-over-year growth 2018-2022 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Rise in population aged 65 and above (% of total) Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: Eli Lilly: Overview Exhibit 45: Eli Lilly: Business segments Exhibit 46: Eli Lilly: Organizational developments Exhibit 47: Eli Lilly: Geographic focus Exhibit 48: Eli Lilly– Segment focus Exhibit 49: Eli Lilly: Key offerings Exhibit 50: F. Hoffmann-La Roche overview Exhibit 51: F. Hoffmann-La Roche– Business segments Exhibit 52: F. Hoffmann-La Roche – Organizational developments Exhibit 53: F. Hoffmann-La Roche– Geographic focus Exhibit 54: F. Hoffmann-La Roche– Segment focus Exhibit 55: F. Hoffmann-La Roche – Key offerings Exhibit 56: Johnson & Johnson overview Exhibit 57: Johnson & Johnson– Business segments Exhibit 58: Johnson & Johnson– Organizational developments Exhibit 59: Johnson & Johnson– Geographic focus Exhibit 60: Johnson & Johnson– Segment focus Exhibit 61: Johnson & Johnson– Key offerings Exhibit 62: Merck: Overview Exhibit 63: Merck: Business segments Exhibit 64: Merck: Organizational developments Exhibit 65: Merck: Geographic focus Exhibit 66: Merck – Segment focus Exhibit 67: Merck-Key offerings Exhibit 68: Novartis: Overview Exhibit 69: Novartis: Business segments Exhibit 70: Novartis: Organizational developments Exhibit 71: Novartis: Geographic focus Exhibit 72: Novartis – Segment focus Exhibit 73: Novartis-Key offerings

Eli Lilly F. Hoffmann-La Roche Johnson & Johnson Merck Novartis